EMBC

SAN FRANCISCO, July 29, 2026 /PRNewswire/ -- Hagens Berman, a leading national shareholder rights law firm, is conducting an investigation into Embecta Corp. (NASDAQ: EMBC) regarding alleged violations of federal securities laws. This investigation follows the recent filing of a class action lawsuit in the U.S. District Court for the District of New Jersey, which alleges that Embecta misrepresented the commercial stability of its insulin pen needle business.

New York, New York--(Newsfile Corp. - July 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC) on behalf of investors that purchased or otherwise acquired Embecta securities between November 25, 2025 and May 4, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Embecta and have suffered losses, you may CLICK HERE to contact us.

Alert: Claims Focus on Alleged Misrepresentations About U.S. Pen Needle Revenue Stability as Embecta's Business Declined Over 14% NEW YORK, July 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Embecta Corp. (NASDAQ: EMBC) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased Embecta securities between November 25, 2025 and May 4, 2026.

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Embecta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/embecta-class-action-lawsuit.

New York, New York--(Newsfile Corp. - July 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 17, 2026 lead plaintiff deadline. SO WHAT: If you purchased Embecta common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK, July 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the "Class Period"), of the importantAugust 17, 2026 lead plaintiff deadline. So what: If you purchased Embecta common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC).   Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

SAN FRANCISCO, July 28, 2026 (GLOBE NEWSWIRE) -- Hagens Berman, a leading national shareholder rights law firm, is conducting an investigation into Embecta Corp. (NASDAQ: EMBC) regarding alleged violations of federal securities laws. This investigation follows the recent filing of a class action lawsuit in the U.S. District Court for the District of New Jersey, which alleges that Embecta misrepresented the commercial stability of its insulin pen needle business.

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Embecta securities between November 25, 2025 and May 4, 2026, both dates inclusive (the “Class Period”).

LOS ANGELES, July 28, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Embecta Corp., (“Embecta” or the "Company") (NASDAQ: EMBC) investors of a class action on behalf of investors that bought securities between November 25, 2025 and May 4, 2026, inclusive (the “Class Period”). Embecta investors have until August 17, 2026 to file a lead plaintiff motion.